Log In
Print
BCIQ
Print
Print this Print this
 

AEZS-134

  Manage Alerts
Collapse Summary General Information
Company Aeterna Zentaris Inc.
DescriptionMAP kinase 3 (MAPK3; ERK-1) and ERK-2 inhibitor
Molecular Target MAP kinase 3 (MAPK3) (ERK-1) ; MAP kinase 1 (MAPK1) (ERK-2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today